(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Safeguarding Your Senior Protection Against Extortion and Tricks.- Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- How to watch NASA's Artemis 2 astronauts launch to the moon on April 1
- The most effective method to Begin Your Excursion in Gold Venture
- Nutrient Rich Organic products: Lift Your Wellbeing
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Thyssenkrupp to suspend electrical steel production at French site
- Canada's Serene Lakeside Mountain Village Is A Breathtaking Oasis For Outdoor Adventure
